NCT03860272 2026-03-30Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled
NCT05941507 2025-09-24A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsLigaChem Biosciences, Inc.Phase 1/2 Recruiting300 enrolled
NCT03104699 2025-07-30A Study of AGEN2034 in Advanced Tumors and Cervical CancerAgenus Inc.Phase 1/2 Completed211 enrolled 29 charts
NCT04152018 2025-05-28Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.PfizerPhase 1 Terminated85 enrolled
NCT03549000 2024-12-13A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.NovartisPhase 1 Terminated127 enrolled
NCT04672434 2024-12-09Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor MalignanciesSymphogen A/SPhase 1 Completed48 enrolled
NCT04864782 2024-01-12QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical CancerQilu Pharmaceutical Co., Ltd.Phase 2/3 Terminated46 enrolled
NCT02607813 2022-12-21Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway AlterationsNovartisPhase 1 Terminated142 enrolled
NCT04943627 2022-10-05Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)Agenus Inc.Phase 3 Withdrawn
NCT02807844 2021-08-11Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed141 enrolled 58 charts